CG From the
-
Legal And IP Protection For New Biotechs
10/31/2023
Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs.
-
A Sneak Peek At REGENXBIO On Cell & Gene: The Podcast
10/30/2023
REGENXBIO's CEO, President, and Director, Ken Mills and I sat down to record an upcoming episode of Cell & Gene: The Podcast. Here's a sneak peak of the episode.
-
Highlights from In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg
10/27/2023
Umoja Biopharma’s Dr. Andrew Scharenberg joined me as my guest on a recent episode of Cell & Gene: The Podcast to discuss the evolution of in vivo CAR-T cell therapeutics. Here are highlights from our conversation.
-
5 Takeaways From Meeting On The Mesa 2023
10/25/2023
This year's conference delivered outstanding networking, presentations, and panel discussions with industry leaders. Here are 5 of my favorite quotes from this year's participants.
-
ARM’s 2023 Meeting On The Mesa: Data, Ethics, And More
10/19/2023
ARM's 2023 Meeting on the Mesa was chock full of informative sessions, impactful conversations, partnering opportunities, and peer networking. Here's a brief recap.
-
Gamida Cell On Improving Natural Killer Cell Therapies
10/16/2023
Gamida Cell CEO and CSO discuss the company's nicotinamide (NAM) technology and its potential to improve natural killer (NK) cell therapy products.
-
September's Top Content On Cell & Gene
9/29/2023
Here is a glimpse of the impactful content, in various formats, Cell & Gene delivered this month.
-
Dr. Jim Wilson At LSPA’s Life Sciences Future Conference
9/28/2023
LSPA's Life Science Future event included a plenary session featuring Jim Wilson Ph.D., M.D., Director, Gene Therapy Program Professor of Medicine and Pediatrics, Perelman School of Medicine at the University of Pennsylvania. Here's a recap of that session.
-
Base Editing And Prime Editing: How They’re Changing Gene Therapy
9/27/2023
I spoke to Beam Therapeutics and Prime Medicine to learn about base editing and prime editing and how they're advancing gene therapies.
-
Universalizing Allogeneic Cell Therapies With Cord-Blood-Derived Stem Cells
9/26/2023
Coeptis Therapeutics' new CSO, Dr. Colleen Delaney, explains why she thinks umbilical cord blood is the best source of starting material for allogeneic cell therapies.